AI in Healthcare

Today's Stories

1. 1

   Thermo Fisher Completes $8.875B Clario Buy, Targets Clinical Trial Data Dominance

   Thermo Fisher Scientific completed an $8.875 billion（約1.4兆円） cash acquisition of Clario Holdings, a clinical trial endpoint data provider, with potential additional payments of $125 million（約200億円） in January 2027 and up to $400 million（約640億円） in earn-outs tied to 2026–2027 performance. The deal was initially agreed upon in October 2025. Clario's platform has supported approximately 70% of FDA and EMA novel drug approvals over the past decade. The acquisition immediately adds $0.45 to adjusted EPS and is expected to deliver approximately $175 million（約280億円） in adjusted operating income from synergies by year five, creating a full-stack infrastructure that integrates clinical trial data with Thermo Fisher's existing CRO business (PPD). However, Thermo Fisher faces a "Switzerland Problem"—competitors like IQVIA, ICON, and Fortrea have historically used Clario's platform, and may hesitate to share sensitive trial data with a now-rival-owned subsidiary.

   Thermo Fisher must balance integrating Clario enough to achieve $175 million（約280億円） in revenue synergies by year five while maintaining sufficient operational independence and perceived neutrality to retain external clients. The company's partnership with NVIDIA on AI-driven analytics will amplify Clario's clinical trial data for accelerated drug discovery; AI algorithms analyzing data from millions of patients could identify correlations and optimize trial designs.

2. 2

   ExaWizards announces wearable device for breast cancer patients

   ExaWizards and ExaMD presented findings from a wearable device study targeting breast cancer patients at the ASCO 2026 Conference held by the American Society of Clinical Oncology (ASCO). The research is a collaborative project involving Kansai Medical University, Daiichi Sankyo, and other institutions. The research represents a collaboration between Japanese AI and healthcare companies and major pharmaceutical and academic institutions, advancing the development of wearable monitoring technology for cancer patients. Presentation at ASCO, a leading international oncology forum, demonstrates that the research meets global clinical standards.

   While specific findings and clinical implications from the wearable device research are set to be detailed in the ASCO 2026 presentation, detailed results have not yet been disclosed in this announcement.

3. 3

   MindWalk Holdings joins Russell 3000E ahead of Q4 earnings

   MindWalk Holdings Corp. (NASDAQ: HYFT), an Austin-based AI drug-discovery company, was added to the Russell 3000E Index effective after the U.S. market close on June 26, 2026. The company will report fourth-quarter and full fiscal year 2026 results on July 22, 2026, at 5:00 p.m. Eastern Time, and has filed a European patent application for its proprietary HYFT Technology and ReefIQ biological context layer. The index inclusion broadens MindWalk's eligibility for index-tracking funds, giving it fresh institutional visibility at a time when AI-driven drug discovery names have been among the market's stronger performers. The company is positioning itself in two major pharmaceutical frontiers—GLP-1 metabolic health and infectious disease—by applying its LensAI platform to programs aimed at sustaining high-quality signaling alongside healthy-aging pathways.

   MindWalk's earnings call on July 22, 2026 will offer investors a near-term look at the company's revenue trajectory and program progress. The company's competitive differentiation rests on HYFT Technology, a proprietary, function-aware representation of biology built on roughly 660 million biological patterns that encode conserved relationships between sequence, structure, and function.

4. 4

   OpenAI researcher Miles Wang raises $200M at $2B for AI drug discovery startup

   Miles Wang, an OpenAI researcher, is leaving to launch a startup focused on AI models for drug discovery. He is in talks to raise about $200 million（約320億円） at a $2 billion（約3200億円） valuation, with Lightspeed in discussions to lead the funding round; several other OpenAI researchers are expected to join. The move reflects investor appetite for AI applied to life sciences. Comparable startups have raised substantial funding—Chai Discovery announced a $400 million（約640億円） raise at a $3.8 billion（約6100億円） valuation this week, and Google DeepMind's Isomorphic Labs raised a $2.1 billion（約3400億円） Series B in May. The new company may focus on finding new uses for existing FDA-approved drugs, which can reach revenue faster than developing drugs from scratch.

   Wang, who joined OpenAI in 2024 after dropping out from Harvard, has co-authored research on how AI models can automate and accelerate scientific discovery. Wang disputed the reported funding figures and company description but did not specify the correct details; talks are ongoing and the deal may not be final.

5. 5

   Amgen, Scientists Say AI Speeds Drug Discovery but Is Not a Shortcut

   Amgen and leading academic institutions held a roundtable conversation (Meeting the Moment) exploring how AI is shaping drug discovery. The discussion underscores that while AI can help teams analyze complex data, generate hypotheses, and identify patterns, it does not replace the scientific process. Developing a new medicine typically takes more than a decade. AI offers the potential to help researchers learn faster, but key challenges remain—including predicting how drugs behave in the human body and ensuring safety. The conversation highlights that real progress depends on high-quality data, deeper biological understanding, and expertise and judgment of scientists working alongside these tools.

   Amgen is investing in this direction through a recent South San Francisco lab expansion designed to support the Design, Make, Test, Analyze (DMTA) process, which brings together chemistry, biology, automation, and data science to generate insights faster and better connect decisions across the research process.

6. 6

   Insilico starts Phase III trial for AI-discovered lung-fibrosis drug

   Insilico Medicine initiated a Phase III clinical trial for Rentosertib, an oral small-molecule inhibitor targeting TNIK for idiopathic pulmonary fibrosis (IPF). The drug was discovered using Insilico's AI platforms—PandaOmics identified TNIK as a high-priority fibrosis target, and Chemistry42 designed the molecule. The Phase IIa trial showed manageable safety and tolerability, with the 60 mg once-daily arm demonstrating mean forced vital capacity improvement of +98.4 mL at 12 weeks. IPF is a progressive lung-scarring disease with median survival commonly reported at approximately two to four years after diagnosis, and current approved antifibrotic therapies can only slow progression but do not reverse the disease. Rentosertib represents a potentially first-in-class medicine whose target was identified by AI, whose chemical structure was designed by generative AI, and whose development is aimed at this severe age-related disease with high unmet medical need. This marks a major late-stage milestone for AI-driven drug discovery moving from research into late-stage clinical validation.

   The Phase III trial is expected to enroll 320 patients with IPF and is designed to systematically evaluate efficacy and safety of once-daily Rentosertib administered over 52 weeks. The trial will be led by Professor Zuojun Xu of Peking Union Medical College Hospital as Leading Principal Investigator, with Academician Nanshan Zhong and President Chang Chen as Co-Leading Principal Investigators.